Warfarin-Fluconazole III - A rational approach to management of a metabolically based drug interaction

Drug Metabolism and Disposition

Volumn 24, Issue 4, 1996, Pages 429-435

  Kunze, Kent L ^a   Trager, William F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUCONAZOLE; TOLBUTAMIDE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; MICHAELIS CONSTANT; PRIORITY JOURNAL; STEADY STATE;

ANTICOAGULANTS; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUCONAZOLE; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE; WARFARIN;

EID: 0029914380     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. D. J. Black, K. L. Kunze, L. C. Wienkers, B. E. Gidal, T. L. Seaton, N. D. McDonnell, J. S. Evans, J. E. Bauwens, and W. F. Trager: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. 24, 422-428 (1996).
2. K. L. Kunze, L. C. Weinkers, K. E. Thummel, and W. F. Trager: Inhibition of the human cytochrome P-450 enzymes responsible for the metabolism of warfarin by fluconazole. I. In vitro studies. Drug Metab. Dispos. 24, 414-421 (1996).
3. N. A. Buckley and A. H. Dawson: Drug interactions with warfarin. Med. J. Aust 157, 479-483 (1992).
4. R. A. O'Reilly: Studies of the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther. 16, 348-354 (1974).
5. D. S. Hewick and J. McEwen: Plasma half-lives, plasma metabolites and the anticoagulant efficacies of the enantiomers of warfarin in man. J. Pharm. Pharmacol. 25, 455-465 (1973).
6. L. B. Wingard, R. A. O'Reilly, and G. Levy: Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clin. Pharmacol. Ther. 23, 212-217 (1978).
7. N. H. G. Holford: Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin. Pharmacokinet. 11, 483-504 (1986).
8. P. A. Routledge, P. H. Chapman, D. M. Davies, and M. D. Rawlins: Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br. J. Clin. Pharmacol. 8, 243-247 (1979).
9. P. Weiss, H. Halkin, and S. Almog: The negative impact of biological variation in the effect and clearance of warfarin on methods for prediction of dose requirements. Thromb. Haemost. 56, 371-375 (1986).
10. M. Pitsiu, E. M. Parker, L. Aarons, B. Holt, and M. Rowland: A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin. Eur. J. Clin. Pharmacol. 42, 645-650 (1992).
11. A. E. Rettie, K. R. Korzekwa, K. L. Kunze, R. F. Lawrence, A. C. Eddy, T. Aoyama, H. V. Gelboin, F. J. Gonzalez, and W. F. Trager: Hydroxylation of warfarin by human cDNA expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
12. S. M. Grant and S. P. Clissold: Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39, 877-914 (1990).
13. J. D. Lazar and K. D. Wilner: Drug interactions with fluconazole. Rev. Inf. Dis. 12, S327-S333 (1990).
14. M. Rowland and S. B. Matin: Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm. 1, 553-556 (1973).
15. P. N. Shaw and J. B. Houston: Kinetics of drug metabolism inhibition: use of metabolic concentration-time profiles. J. Pharmacokinet. Biopharm. 15, 497-510 (1987).
16. A. Adedayo, L. E. Aarons, and J. B. Houston: Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat. Drug Metab. Dispos. 15, 127-132 (1987).
17. S. Toon, L. K. Low, M. Gibaldi, W. F. Trager, R. A. O'Reilly, C. H. Notley, and D. A. Goulart: The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin. Pharmacol. Ther. 39, 15-24 (1986).
18. L. D. Heimark, L. C. Wienkers, K. L. Kunze, M. Gibaldi, A. C. Eddy, W. F. Trager, R. A. O'Reilly, and D. A. Goulart: The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407 (1992).
19. R. A. O'Reilly, D. A. Goulart, K. L. Kunze, J. Neal, M. Gibaldi, A. C. Eddy, and W. F. Trager: Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. 51, 656-667 (1992).
20. M. Gibaldi and D. Perrier: "Pharmacokinetics," 2nd ed. Marcel-Dekker. New York, 1982.
21. L. L. Crussell-Porter, J. P. Rindone, M. A. Ford, and D. W. Jaskar: Lowdose fluconazole therapy potentiates the hypoprothrominemic response of warfarin sodium. Arch. Intern. Med. 153, 102-104 (1993).
22. J. R. Koup, R. D. Toothaker, E. Posvar, A. J. Sedman, and W. A. Colburn: Theophylline dosage adjustment during enoxacin coadministration. Antimicrob. Agents Chemother. 34, 803-807 (1990).
23. M. E. Veronese, P. I. Mackenzie, C. J. Doecke, M. E. McManus, J. O. Miners, and D. J. Birken: Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Comm. 175, 1112-1118 (1991).
24. M. E. Veronese, C. J. Doecke, P. I. Mackenzie, M. E. McManus, J. O. Miners, D. L. Rees, R. Gasser, U. A. Meyer, and D. J. Birkett: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J. 289, 533-538 (1993).
25. A. E. Rettie, L. C. Wienkers, F. J. Gonzalez, W. F. Trager, and K. R. Korzekwa. Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42 (1994).
26. M. E. Veronese, J. O. Miners, D. Randles, D. Gregov, and D. J. Birkett: Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabotizers. Clin. Pharmacol. Ther. 47, 403-411 (1990).
27. D. J. Back, J. F. Tjia, J. Karbwang, and J. Colbert: In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26, 23-29 (1988).
28. C. M. Ervine and J. B. Houston: Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver. Pharmaceut. Res. 11, 961-965 (1994).
29. R. A. Blum, J. H. Wilton, D. M. Hilligoss, M. J. Gardner, E. B. Henry, N. J. Harrison, and J. J. Schentag: Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 4, 420-425 (1991).